Kynam Capital Management, LP Viridian Therapeutics, Inc.\De Transaction History
Kynam Capital Management, LP
- $1.19 Billion
- Q1 2025
A detailed history of Kynam Capital Management, LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Kynam Capital Management, LP holds 4,700,000 shares of VRDN stock, worth $60.6 Million. This represents 5.34% of its overall portfolio holdings.
Number of Shares
4,700,000
Previous 3,326,262
41.3%
Holding current value
$60.6 Million
Previous $63.8 Million
0.64%
% of portfolio
5.34%
Previous 4.04%
Shares
14 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.8MCall Options Held
419KPut Options Held
686K-
Deep Track Capital, LP Greenwich, CT5.38MShares$69.4 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$61.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$58.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$50.1 Million12.28% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$44.5 Million13.28% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $515M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...